Dublin, February 18, 2021/PRNewswire/-ResearchAndMarkets.com has added the “China Botox Type A Market Survey Report 2020-2024″ to the products.
On April 15, 2002, botulinum toxin type A was approved by the FDA as a medical cosmetic for temporarily improving the appearance of moderate to severe glabellar lines. Later, some generic drugs appeared on the market. In addition to imported type A botulinum toxin (trade name: Botox) produced by Allergan, China’s type A botulinum toxin products also include type A botulinum toxin developed by Lanzhou Institute of Biological Products Co., Ltd. (Trade name: Hengli).
According to this market survey, botulinum toxin type A has grown rapidly since it entered China. From 2015 to 2019, its annual sales increased from less than RMB 104.88 million to RMB 176.54 million, with a compound annual growth rate of 13.9%.
In China, the medical use of botulinum type A is to treat adult blepharospasm and anterior back spasm and some strabismus, especially acute paralytic strabismus, concomitant strabismus, strabismus caused by endocrine diseases, and inoperable correction for 12 years and older Squint. The incidence of facial neuropathy in China is on the rise. Many people suffer from forelimb spasms when they are stressed or tired. The global annual incidence rate is about 0.003%. Facial neuropathy is more common in women than men. Middle-aged and elderly people are more common in other age groups.
However, more users of botulinum toxin type A are women who are pursuing face-lifting or reducing wrinkles. There are more than 10 million cosmetic surgeries each year. In 2019, China’s medical aesthetics market has exceeded 15 billion U.S. dollars and is still growing. As the demand for type A botulinum continues to expand, some medical institutions and beauty salons have begun to inject their customers with type A botulinum smuggled from South Korea, France, Germany and other places. Although the Chinese government only approved the sale of botulinum toxin and Hengli, smuggled type A botulinum toxin products are easily available in China.
It is expected that with the development of China’s economy, the increase of income and the change of consumption habits, Chinese people’s expenditure on medical beauty will increase, and the market size of type A botulinum in China will continue to grow in 2020-2024. Topics covered:
1 Related concepts of type A botulinum 1.1 indications of type A botulinum 1.2 development of type A botulinum in China 1.3 Chinese government approval of type A botulinum 2 sales of type A botulinum in China from 2015 to 2019 2.1 Sales value 2.1.1 China Type A Botox total sales 2.1.2 Sub-regional sales 2.2 China Type A Botox sales 2.2.1 Total sales 2.2.2 Sub-regional sales 2.3 Type A Botox sales 2015-2019 China Analysis of main dosage forms 3 2015-2019 China’s type A botulinum major manufacturers market analysis 3.1 type A botulinum major manufacturers market share analysis 3.1.1 market share (by sales) 3.1.2 market 3.2 Allergan 3.2.1 Company Profile 3.2.2 Sales of Allergan Botox Type A in China 3.3 Lanzhou Institute of Biological Products Co., Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Lanzhou Institute of Biological Products Co., Ltd. in China Botulinum toxin type A 3.4 Analysis of botulinum toxin type A illegally sold in China 4 The price of botulinum toxin type A in China, 2019-2020 4.1 Average price of botulinum toxin type A in China, 2019-20204.2 Allergan A Average price of type A botulinum (Botox) 4.3 Average price of type A botulinum (Henli) of Lanzhou Institute of Biological Products Co., Ltd. 5 2020-2024 China’s type A botulinum market outlook 5.1 Main influencing factors affect China’s type A Botulinum toxin market development 5.2 Market size forecast 5.3 Market trend forecast
Post time: Aug-02-2021